Mode
Text Size
Log in / Sign up

Meta-analysis finds no significant association between statin use and sarcopenia in older adultsLarge review finds no clear link between statin use and muscle loss in older adults

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Interpret the lack of statin-sarcopenia association cautiously due to high heterogeneity in evidence.

A systematic review and meta-analysis examined observational studies investigating the association between statin use and the development of sarcopenia in predominantly older adults aged 60 years and above from European and Asian populations. The analysis included a total of 9,080 participants. The comparator group was not consistently reported across the included studies.

The primary finding was no statistically significant association between statin exposure and sarcopenia, with a pooled odds ratio of 0.82 (95% confidence interval: 0.16 to 4.05). The direction of estimates from individual studies ranged from potentially harmful to mildly protective, but the overall meta-analysis did not reach statistical significance. Safety and tolerability data were not reported in the meta-analysis.

Key limitations severely restrict the interpretability of these findings. The analysis demonstrated extremely high statistical heterogeneity (I² = 99.6%), indicating substantial inconsistency in results across the included studies. There was also limited methodological consistency in how sarcopenia was defined and measured. The evidence is observational and cannot establish causation.

For clinical practice, this analysis does not provide clear evidence that statin use is associated with sarcopenia risk in older adults. However, the high heterogeneity and methodological inconsistencies mean the question remains unresolved. Clinicians should continue to monitor for muscle symptoms as part of routine statin management while recognizing the current evidence base is inconclusive regarding a specific link to sarcopenia.

Researchers conducted a systematic review and meta-analysis to examine whether taking statin medications is associated with developing sarcopenia in older adults. Sarcopenia is the age-related loss of muscle mass and strength. The analysis combined data from multiple studies, involving a total of over 9,000 participants aged 60 and older, primarily from European and Asian populations.

The main finding was that there was no statistically significant association between statin use and the development of sarcopenia. The combined result showed a pooled odds ratio of 0.82, but the confidence interval was very wide (95% CI: 0.16 to 4.05). This means the data from all the studies together suggests effects ranging from a possible mild protective effect to a possible harmful effect, but none were statistically clear.

It is very important to be cautious with this result. The review found extremely high heterogeneity (I² = 99.6%), meaning the individual studies included were very different from each other in their methods and findings. There was also limited consistency in how the studies were conducted. This makes the overall result difficult to interpret reliably.

Readers should understand that this analysis does not provide strong evidence that statins either cause or prevent sarcopenia in older adults. The evidence is observational, which means it can show a link but cannot prove cause and effect. The high variability between studies means more consistent, high-quality research is needed. If you are an older adult taking statins, do not stop or change your medication based on this review. Always discuss any concerns about muscle health with your doctor.

What this means for you:
A large review found no clear evidence linking statins to muscle loss in older adults, but the results are uncertain due to major differences between studies.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Given the ongoing debate regarding whether statin therapy contributes to muscle decline in older adults, this study aims to synthesize the available observational evidence on the association between statin use and the development of sarcopenia through a systematic review and meta-analysis. METHODS: Following PRISMA 2020 and MOOSE guidelines, searches were conducted in PubMed, Scopus, and Web of Science. Effect estimates from eligible observational studies were extracted and pooled using random-effects models with the Paule-Mandel estimator. One meta-analysis assessed the association between statin exposure and sarcopenia; a meta-regression explored whether study-level factors modified the relationship. RESULTS: Ten studies met the inclusion criteria (total n = 9080), enrolling predominantly adults aged ≥60 years from European and Asian populations. The meta-analysis yielded a pooled odds ratio of 0.82 (95% CI: 0.16-4.05), indicating no statistically significant association between statin use and sarcopenia. Heterogeneity was extremely high (I = 99.6%). The meta-regression, based on available moderators (e.g., malnutrition, obesity, disability level), did not identify significant predictors of variability across studies. CONCLUSIONS: Statin exposure was not associated with an increased risk of sarcopenia in older adults. Although estimates ranged from potentially harmful to mildly protective, high heterogeneity and limited methodological consistency restrict interpretability.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.